Skip to content
Commercial Litigation Woods Lonergan LLP

212.684.2500

Copyright Litigation

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ...
GlobeNewswire (press release)
These risks and uncertainties include, without limitation, risks associated with designing and conducting clinical trials; the fact that preliminary results of ongoing clinical trials or results of past clinical trials may not be predictive of ongoing ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ...
GlobeNewswire (press release)
These risks and uncertainties include, without limitation, risks associated with designing and conducting clinical trials; the fact that preliminary results of ongoing clinical trials or results of past clinical trials may not be predictive of ongoing ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ...
GlobeNewswire (press release)
These risks and uncertainties include, without limitation, risks associated with designing and conducting clinical trials; the fact that preliminary results of ongoing clinical trials or results of past clinical trials may not be predictive of ongoing ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ...
GlobeNewswire (press release)
These risks and uncertainties include, without limitation, risks associated with designing and conducting clinical trials; the fact that preliminary results of ongoing clinical trials or results of past clinical trials may not be predictive of ongoing ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA ...
GlobeNewswire (press release)
These risks and uncertainties include, without limitation, risks associated with designing and conducting clinical trials; the fact that preliminary results of ongoing clinical trials or results of past clinical trials may not be predictive of ongoing ...

and more »

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on ...
GlobeNewswire (press release)
In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation ...

and more »

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ... - GlobeNewswire (press release)

January 8, 2018 - 7:31am

Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints ...
GlobeNewswire (press release)
... risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability ...

and more »

Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in ... - GlobeNewswire (press release)

January 8, 2018 - 7:15am

Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in ...
GlobeNewswire (press release)
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced new preclinical data ...

and more »

Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and ... - GlobeNewswire (press release)

January 8, 2018 - 7:05am

Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and ...
GlobeNewswire (press release)
DUBLIN, Ireland, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), today provided updates on the potential performance of key growth drivers and its research and development (R&D) pipeline. “The increase in our sales expectations for ...

and more »

Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered ... - GlobeNewswire (press release)

January 8, 2018 - 7:01am

Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered ...
GlobeNewswire (press release)
... Orphan and/or Fast Track designations for MAT2203, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to protect the Company's intellectual property; the loss ...

and more »

Microbot Medical Enters into Agreement to Acquire Novel ... - GlobeNewswire (press release)

January 8, 2018 - 7:00am

Microbot Medical Enters into Agreement to Acquire Novel ...
GlobeNewswire (press release)
HINGHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today announced that it entered into ...

and more »

K2M Group Holdings, Inc. Reports Preliminary Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)

January 8, 2018 - 6:45am

K2M Group Holdings, Inc. Reports Preliminary Fourth Quarter and Full Year 2017 Financial Results
GlobeNewswire (press release)
... continuing worldwide economic instability; our ability to protect our intellectual property rights; patent litigation and product liability lawsuits; damages relating to trade secrets or non-competition or non-solicitation agreements; risks ...

and more »

AMD Redefines High-Performance Computing with New Processor and Graphics Products Preview at CES 2018 - GlobeNewswire (press release)

January 8, 2018 - 12:01am

NDTV

AMD Redefines High-Performance Computing with New Processor and Graphics Products Preview at CES 2018
GlobeNewswire (press release)
Fluctuations in demand for AMD's products or a market decline in any of these industries could have a material adverse effect on its results of operations; AMD's ability to design and introduce new products in a timely manner is dependent upon third ...
New 8th Gen Intel Core Processors with Radeon RX Vega M Graphics Offer 3x Boost in Frames per Second in Devices ...Intel Newsroom

all 66 news articles »